Who’s Hired? Medicines For Europe Names Stada’s Eder As President

As IGBA Reveals New Chair And Firms Announce Fresh Appointments

13 Jan 2025

Medicines for Europe names a new president, the IGBA reveals its latest chair, and Chanelle and Xbrane announce fresh faces in key roles, in our latest round-up of off-patent industry appointments.

Industry associations have named new leaders at the start of 2025 (Shutterstock)

European off-patent industry association Medicines for Europe has named Stada’s head of western Europe and Germany, Stephan Eder, to become the industry body’s new president for a two-year term.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

24 Apr 2025

• By Dave Wallace

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

Samsung Bioepis Reevaluating Approach To Biosimilars

22 Apr 2025

• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Cardinal Looks Ahead To A New Decade For US Biosimilars

20 Apr 2025

• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

01 Apr 2025

• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

Sunshine Becomes Latest To Compete On Everolimus In Canada

23 Apr 2025

• By Dave Wallace

Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.